US Patent No. 9,075,066

CST1, DCC1, IFITM1, or MELK as markers for diagnosing stomach cancer
Jul 23, 2015

Korea Research Institute of Bioscience and Biotechnology has been awarded US Patent No. 9,075,066, "CST1, DCC1, IFITM1, or MELK as markers for diagnosing stomach cancer."

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Sponsored by
Genialis & Roche

While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.